- Home
- GMAB vs INCY Comparison
GMAB vs INCY Comparison
Compare GMAB & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- INCY
- Stock Information
- Founded
- GMAB 1999
- INCY 1991
- Country
- GMAB Denmark
- INCY United States
- Employees
- GMAB N/A
- INCY N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- GMAB Health Care
- INCY Health Care
- Exchange
- GMAB Nasdaq
- INCY Nasdaq
- Market Cap
- GMAB 12.1B
- INCY 13.4B
- IPO Year
- GMAB N/A
- INCY 1993
- Fundamental
- Price
- GMAB $24.14
- INCY $70.79
- Analyst Decision
- GMAB Buy
- INCY Buy
- Analyst Count
- GMAB 9
- INCY 19
- Target Price
- GMAB $40.71
- INCY $74.38
- AVG Volume (30 Days)
- GMAB 1.2M
- INCY 1.9M
- Earning Date
- GMAB 05-01-2025
- INCY 04-29-2025
- Dividend Yield
- GMAB N/A
- INCY N/A
- EPS Growth
- GMAB 83.82
- INCY N/A
- EPS
- GMAB 16.85
- INCY 0.15
- Revenue
- GMAB $2,988,286,182.00
- INCY $4,241,216,999.00
- Revenue This Year
- GMAB $19.59
- INCY $12.23
- Revenue Next Year
- GMAB $14.50
- INCY $8.89
- P/E Ratio
- GMAB $14.08
- INCY $420.04
- Revenue Growth
- GMAB 30.67
- INCY 14.76
- 52 Week Low
- GMAB $18.64
- INCY $50.35
- 52 Week High
- GMAB $31.88
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- INCY 46.65
- Support Level
- GMAB $23.63
- INCY $68.17
- Resistance Level
- GMAB $24.11
- INCY $76.24
- Average True Range (ATR)
- GMAB 0.37
- INCY 2.03
- MACD
- GMAB 0.22
- INCY -0.23
- Stochastic Oscillator
- GMAB 93.88
- INCY 32.47
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.